N Aghdami

Publications (2)6.43 Total impact

• Article: Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy.

  A Ghavamzadeh, K Alimoghaddam, S H Ghaffari, S Rostami, M Jahani, R Hosseini, A Mossavi, E Baybordi, A Khodabadeh, M Iravani, B Bahar, Y Mortazavi, M Totonchi, N Aghdami
  [show abstract] [hide abstract]
  ABSTRACT: Arsenic trioxide is effective and approved for treatment of relapsed or refractory acute promyelocytic leukemia (APL) cases resistant to all-trans retinoic acid (ATRA), but its effect on new cases of APL is not clear. We studied 111 patients with APL. Arsenic trioxide was infused at 0.15 mg/kg daily dose, until complete remission was achieved. Then, after 28 days of rest, arsenic trioxide was infused daily for 28 days as consolidation therapy. We studied minimal residual disease (MRD) by semi-sensitive reverse transcription polymerase chain reaction (RT-PCR) on peripheral blood samples. Complete remission was observed in 95 patients (85.6%). With the median (range) follow-up period of 16.5 (1-57) months, 1- and 2-year disease-free survival was 88.3% and 63.7%, respectively; 24 patients relapsed, 19 of whom achieved a second complete remission, again by arsenic trioxide. Third and fourth remissions were seen in some relapsed patients, again by arsenic trioxide. For patients in complete remission, 1- and 3-year survival was 95.5% and 87.6%, respectively. MRD was positive in four (8.3%) out of 48 cases during 1 year after remission induction; three of them relapsed clinically. Arsenic trioxide is effective as first-line treatment for APL. Results of arsenic trioxide combination therapy with chemotherapy/ATRA requires further study.
  Annals of Oncology 02/2006; 17(1):131-4. · 6.43 Impact Factor
• Source

  Available from: who.int

  Article: Urinary iodine/creatinine ratio in patients with stomach cancer in Urmia, Islamic Republic of Iran.

  R Behrouzian, N Aghdami
  [show abstract] [hide abstract]
  ABSTRACT: We carried out a case-control study is to investigate the relationship between iodine deficiency and stomach cancer. We compared the ratio of urinary iodine to urinary creatinine in 100 patients diagnosed with stomach cancer and 84 people in a control group. Mean urinary iodine levels were lower in the patients with stomach cancer, 61.9 microg/g creatinine, compared to 101.7 microg/g creatinine in the control group (P < 0.0001). More of the cancer patients (49.0%) had severe iodine deficiency (< 25 microg/g creatinine) than people in the control group (19.1%) (P< 0.0001). We found the relationship between stomach cancer and iodine deficiency to be significant.
  Eastern Mediterranean health journal = La revue de santé de la Méditerranée orientale = al-Majallah al-ṣiḥḥīyah li-sharq al-mutawassiṭ 12/2004; 10(6):921-4.